Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Drug reference
pemigatinib
FGFR1–3 kinase inhibitor · Antineoplastic agent
FGFR1–3 kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AmprenavirSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
- AprepitantSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
Mechanism
Pemigatinib is an orally bioavailable selective FGFR1–3 kinase inhibitor.
Indications
pretreated, locally advanced, or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangementFGFR1-rearranged myeloid/lymphoid neoplasms (e.g., 8p11 myeloproliferative syndrome)
Pharmacokinetics
Half-life
15.4 h
Metabolism
CYP3A
Side effects
Common
diarrheahyperphosphatemia (resulting in soft-tissue mineralization and vascular and myocardial calcification)
Serious
- ocular toxicity
Pregnancy & lactation
Pregnancy
D
Drug interactions
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Aprepitant
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Berotralstat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bosentan
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cenobamate
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Chloramphenicol
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ciprofloxacin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Blood transfusion in obstetrics and gynaecology
FOGSI · Obstetrics & Gynaecology · 2024
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Sjögren's syndrome
EULAR · Rheumatology · 2025
Acute coronary syndrome
ESC · Cardiology · 2023
Other FGFR1–3 kinase inhibitor drugs
Ask House about pemigatinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team